Clinician Comments

"I recently needed to insert an interim look 20% of the way into a trial, because of unexpectedly slow accrual. Using East, it took me just one day to make the adjustment, and I know everything is accurate. Without East, I don't know what I would have done. It probably would have taken a whole week of work. East is absolutely instrumental to my work."

Avital Cnaan Ph.D.
Director of Biostatistics and Epidemiology
Children’s Hospital of Philadelphia

"East’s elegant user interface makes sequential designs very straightforward. We have East on every statistician’s desktop. The benefits are clear – we recently used East to insert interim looks into a study on colon cancer, and by crossing a null boundary early we decreased time to publication by two years."

Paul Catalano, Ph.D.
Associate Chair
Department of Biostatistical Science
Dana-Farber Cancer Institute

"I started using East as a statistical review tool during my tenure at the FDA/CDER, and have continued to use it as an industry statistician to design and analyze flexible and group sequential studies because of its user friendliness and industry wide acceptance. Because East is used widely by both industry and regulatory statisticians, I think it is now much easier for industry statisticians to communicate with regulatory statisticians regarding study designs and analysis results based on the software.”

A.J. Sankoh, Ph.D.
Senior Global Biostatistics Manager
Aventis Pharmaceuticals, New Jersey

Reviews

Review of East PDF
by Dan Anbar , Ph.D., President, Millenium Biostatistics.

Review of East PDF
by A. J. Sankoh , Ph.D., Center for Drug Evaluation and Research,
U.S. Food and Drug Administration, Rockville, Maryland.
Drug Information Journal, Vol. 33, pp. 165-176, 1999.